<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02858245</url>
  </required_header>
  <id_info>
    <org_study_id>16-6001</org_study_id>
    <nct_id>NCT02858245</nct_id>
  </id_info>
  <brief_title>A Feasibility Registry of Actigraphy Monitoring in Degenerative Mitral Regurgitation Subjects Receiving the MitraClip® Device</brief_title>
  <acronym>VELOCITY</acronym>
  <official_title>A Feasibility Registry on Use of Actigraphy Monitoring in Degenerative Mitral Regurgitation (DMR) Subjects Receiving the MitraClip® Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, open-label, and multi-centered feasibility registry.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open-label, and multi-centered feasibility registry (single arm
      study). Approximately 36 subjects with prohibitive risk degenerative mitral regurgitation
      (DMR) who receive at least 1 commercial MitraClip will be registered at up to 10 US sites.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study has been terminated due to small sample size
  </why_stopped>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Observational change in daily reported activity levels (counts/min) as assessed by actigraphy, from baseline to 30 days post MitraClip implantation</measure>
    <time_frame>At 30 days</time_frame>
    <description>Phillips Actiwatch Spectrum PRO is the device being used to capture the primary outcome measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of daily and weekly activity as assessed by actigraphy</measure>
    <time_frame>Pre-procedure (on day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of daily and weekly activity as assessed by actigraphy</measure>
    <time_frame>Post-procedure (≤ 7 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of daily and weekly activity as assessed by actigraphy</measure>
    <time_frame>At 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of daily and weekly activity as assessed by actigraphy</measure>
    <time_frame>At 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of daily and weekly activity as assessed by actigraphy</measure>
    <time_frame>At 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of daily and weekly activity as assessed by actigraphy</measure>
    <time_frame>At 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of daily and weekly activity as assessed by actigraphy</measure>
    <time_frame>At 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of daily Sleep/Wake by actigraphy</measure>
    <time_frame>At 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>At Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>At 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Regurgitation severity</measure>
    <time_frame>At Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Regurgitation severity</measure>
    <time_frame>Post-procedure (≤ 7 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Regurgitation severity</measure>
    <time_frame>At 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic assessment</measure>
    <time_frame>At Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic assessment</measure>
    <time_frame>Post-procedure (≤ 7 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic assessment</measure>
    <time_frame>At 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distance walked 6 minute walk test (6MWT)</measure>
    <time_frame>At Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distance walked 6 minute walk test (6MWT)</measure>
    <time_frame>At 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (QoL)</measure>
    <time_frame>At Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (QoL)</measure>
    <time_frame>At 30 days</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>Commercial MitraClip® patients</arm_group_label>
    <description>Patients with Degenerative Mitral Regurgitation receiving MitraClip® Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention - registry</intervention_name>
    <arm_group_label>Commercial MitraClip® patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Prohibitive risk degenerative mitral regurgitation (DMR) patients who receive at least 1
        commercial MitraClip
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must consent to receiving the MitraClip device

          -  Subject must consent, be able, and commit to wearing the Actiwatch continuously for
             approximately 7 months

          -  Subject must consent to use of their data from this registry for purposes of
             exploratory research and publication and presentation

        Exclusion Criteria:

          -  Subject is not a member of vulnerable population

          -  Subject must not have any disabilities that preclude reliable data collection from the
             Actiwatch, e.g., epilepsy with uncontrolled recurring episodes, serious stage
             degenerative/disabling disease (e.g. Parkinson's disease), inability to walk or will
             require walking aids, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Staehr, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Vascular</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner University Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Hospital of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Foundation for Medical Education and Research</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon Secours St Mary's Hospital</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2016</study_first_submitted>
  <study_first_submitted_qc>August 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2016</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MitraClip</keyword>
  <keyword>Structural Heart Failure</keyword>
  <keyword>Degenerative Mitral Regurgitation (DMR)</keyword>
  <keyword>Actigraphy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

